Licensed Clinical Psychologist and a Priest in the Episcopal Church Presents a Handbook to Help Bring Readers Closer to Christ

Reno, Nevada – WEBWIRE

Julius M. Rogina, Ph.D., ABMPP, a licensed clinical psychologist and a priest in the Episcopal Church, Diocese of Nevada, offers “Pilgrimage to Discipleship: A Guide to the Spiritual Exercises of Ignatius Loyola” to spiritually curious people who are looking for new ways of understanding and experiencing spiritual pilgrimage.

The book provides a concise overview of St. Ignatius Loyola’s Spiritual Exercises. Its goal is to assist someone on a one-of-a-kind Christian Spiritual Pilgrimage of faith. Using insights from modern psychology and insights from one of the great masters of Christian Spirituality, the reader is introduced to the five major movements of Christian spiritual living. Understanding human brokenness, encountering Jesus of Nazareth and the Christ of Christian liturgy, coming to grips with human suffering and redemption, living with resurrection hope, receiving God’s Holy Breath, discernment criteria, and the election is just a few of the subjects covered. It discusses how to play an active role in selecting a spiritual companion and reaping the benefits of ongoing spiritual guidance.

“Pilgrimage to Discipleship,” like many other spiritual growth books, is a fascinating read. However, going into, evaluating, following, and performing the Exercises as honestly as possible may be a life-changing and journey-freeing experience. It’s a step-by-step guide to personal growth and discovery in the wonder of a growing personal relationship with God. It’s a beautiful companion for going from knowing about God to knowing God.

Get your copy. Buy the book at:

“Pilgrimage to Discipleship: A Guide to the Spiritual Exercises of Ignatius Loyola”

Author: Julius M. Rogina

Publisher: Your Online Publicist

Published Date: January 2022

Book Genre: Religion & Spirituality

About the Author:

Julius M. Rogina, Ph.D., ABMPP is a licensed clinical psychologist and a priest in the Episcopal Church, Diocese of Nevada. He has worked in inpatient and outpatient clinical settings for the last forty years. He assists Christian Communities with conflict resolutions and discernment process. He has taught in several Universities in the field of psychology and spirituality. The current faculty position with the Medical School, Department of Psychiatry and Behavioral Sciences involves him with a psychiatry residency program in the supervision of psychotherapy. His teachings and writings focus on the integration of Psychology and Christian Spirituality. As a former Jesuit priest and now Episcopal priest, he brings a Christian spiritual dimension to his clinical practice and writings. He and his family reside in Reno, Nevada.

Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 – Best Contract Research Organization in APAC

Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has been selected as a finalist for the Best Contract Research Organization in APAC by Informa Pharma Intelligence.
Avance Clinical has undergone significant expansion in recent years, including new offices in Sydney and Melbourne to accommodate the growing clinical team in Australia.

The award winner will be announced on 1 September 2022. The finalists are:
– Avance Clinical
– Calyx
– CMIC Group
– Parexel
– Syneos Health

Avance Clinical’s CEO Yvonne Lungershausen said:

“Avance Clinical is extremely pleased to be selected as a finalist for this prestigious award. It is a credit to our amazing customer-focused team for delivering the CRO excellence that has been recognized by the Informa Pharma Intelligence award judges.

“Avance Clinical has a global reputation for agile clinical solutions to support accelerated clinical development for our international biotech clients. We are very proud of our growth and success in APAC in recent years.”

According to Informa Pharma Intelligence:

This Award is to recognize CROs that provide full or specialist services to their clients and which have an office in either in Japan or the Asia region including Australia.

Judging considers the quality of services and relationships built with clients and pays particular attention to the innovative patient recruitment strategies the CRO has brought to the table.

The award is based on achievements in the 2021 calendar year.

Core areas judged include:
– The particular capabilities and strengths the CRO offers
– How the company has delivered results that exceed sponsor expectations
– Innovations in patient recruitment strategy has the CRO brought to its partner
– How it has improved its performance, for example, in its quality of data, timelines and transparency
– The steps the company is taking towards streamlining data collection and reporting

To find out more please visit:

Avance Clinical recently secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m.

“With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions,” said Lungershausen.

Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.

The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies.

“We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector,” said Lungershausen.

Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.

Find out more:
– Learn about the Australian Advantage here
– Read more about Avance Clinical’s cell and gene therapy capabilities here
– For more information about the benefits of running your next study with Avance Clinical contact us:

About Avance Clinical

Avance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company’s clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.

Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.

Media Contacts:
Avance Clinical
Chris Thompson

Topic: Press release summary

Clinical PURSUIT’s Enterprise Clinical EDC Allows Researchers to Scale Their Data Management Operations with a Single Click

 Clinical PURSUIT has leveraged Enterprise Solutions to optimize data integration and flow in their Electronic Data Capture Software (EDC). Enterprise Solutions use privately hosted server environments with redundancy for data storage, making it easier to organize data access and operations management.

By incorporating their advanced enterprise solutions into their EDC software, Clinical PURSUIT has converted its EDC into an EDC-CTMS (Clinical Trial Management Software) hybrid. The reason is that the software can now access trial schedules, drug supply information, treatment plans, etc., match them to data capture, and automatically update fields with relevant information.

These intelligent data transfers and updates allow researchers to generate trial reports and analytics with a single click instead of manually organizing information to achieve the same results.

About Clinical Pursuit

ClinicalPURSUIT ( has been in the industry for over 20 years and is renowned for its innovative clinical trial data management and patient registry solutions. It has a diverse team of experts who leverage its competencies to develop multi-dimensional technological solutions for clinical trials.

Their clinical trial management solutions have user-friendly interfaces, simplified dashboards, and consolidated data controls, enabling researchers to spend less time on routine tasks. It makes the clinical trial run efficiently and gives researchers more time to consider alternate approaches for developing treatments.

– Rapid Study Development

– Streamlined EDC Data Management

– Intelligent Electronic Data Capture (EDC)

– Electronic Patient-Reported Outcomes (ePro)

– Enterprise Clinical Electronic Data Capture

– Patient Registry

Significance of Enterprise Clinical Electronic Data Capture

Clinical trials gave three key areas that require data optimization:

– Data Capture

– Data Management

– Drug Supply Management

Clinical EDC software was initially designed to manage only data capture. However, the Clinical PURSUIT team has used creativity and innovation to make their EDC a hybrid system that contains all three features for clients who need such solutions.

Their Enterprise Clinical Electronic Data Capture connects their data capture software to trial management software, thus optimizing data monitoring. The system automatically updates relevant categories after capturing treatment response data, making it easy for researchers to monitor and manage trial updates from a single dashboard.

This simplified control makes the process significantly efficient and reduces the time it takes researchers to conclude trials.

Company Contact Information

ClinicalPURSUIT offers clinical trial management and data management solutions to organizations involved in clinical research. More information about the business is available on their website ( can also be made by emailing or calling 877-791-4367.


Jim Harris




  • Business
  • Medical & Health
  • Software
  • Technology

Clinical Evaluation of LeSoleil Against COVID-19

Since February 2020, when Suntrap Life Technologies Ltd established a COVID-19 project for drug discovery, the Suntrap research team has evaluated and prudently predicted the characteristics of COVID-19. Utilizing the proprietary S-CPDD drug design and discovery system and IDDNU(R) (International Drug Design Network Union) platforms in accordance with scientific laws of drug discovery, Suntrap’s research team has tracked and analyzed the pathological characteristics, clinical needs, pathogenesis research and social demands of patients. In terms of the determination of the direction of drug research and development (R&D), COVID-19 drug related targets acquisition, molecular design and screening, and preclinical verification, the new drug R&D in the Suntrap research team is fully guided by clinical values. It will be standard for the Suntrap team to quickly transform biomedical research into industrial products, and ultimately develop new pharmaceutical products that benefit the public, thus realizing the fundamental significance of new drug R&D.

The Suntrap team believes that the prevention and treatment of COVID-19 should focus on the development of multi-targeted and broad-spectrum anti-coronavirus drugs.

In May 2020, the Suntrap research team identified a lead compound “LeSoleil-T” through a series of bioassays, which showed anti-coronavirus activities with multi-targets inhibition effects. Further studies revealed that the multi-targets design properties of LeSoleil-T could meet the demands of broad-spectrum anti-coronavirus.

In view of the inhibitory effects of LeSoleil-T against SARS-CoV-2, the pharmacological mechanisms of LeSoleil-T were explored through a series of experimental assays. The results showed that LeSoleil-T has pharmacological effects in the treatment of SARS-CoV-2 infection as the following: broad-spectrum anti-coronavirus inhibitory effects, anti-inflammatory effects, neuron protections, delay and reversal of tissue fibrosis.

Based on the above results, the Suntrap team has obtained the Chinese invention patent authorization for the broad-spectrum anti-coronavirus in January 2021, and has filed international patent applications through the PCT, and applied for patent protection in many countries and regions.

According to clinical investigations, upon SARS-CoV-2 infection, the levels of the neutrophil count, D-dimer, blood urea and creatinine in patients will increase continuously, while the count of lymphocytes will continue to decline until death. The Suntrap team found that LeSoleil-T could eliminate inflammation induced by SARS-CoV-2 infection. The anti-inflammatory effects of LeSoleil-T are mainly to inhibit proinflammatory factor expression and reduce oxidative stress responses. Firstly, LeSoleil-T can inhibit neutrophil aggregation to reduce the production of 4-HNE (4-hydroxynonenal) by oxidative stress response, which leads to the reduction of the lipid peroxidation end-product formation, and finally, contribute to its anti-inflammatory activity. Secondly, LeSoleil-T directly inhibits the expression of proinflammatory factors (e.g., Tnf-α, IL-1β, IL-6, Mcp-1, Mcp-2, and Mip-1α). Finally, it activates the interactions among PGC-1α (Peroxisome proliferator-activated receptor-γ coactivator), Nrf1 (Nuclear Respiratory Factor 1) and Nrf2 (Nuclear Respiratory Factor 2) to regulate the mitochondrial synthesis, respiration, and various antioxidant enzymes. Meanwhile, the Nrf2/ARE (antioxidant response element) complex scavenges free radicals by regulating the expression of HO-1 (heme oxygenase-1).

Based on the clinical symptoms and pathogenic mechanism of patients infected with SARS-CoV-2, the Suntrap research team optimized and developed different clinical protocols. The basic formulation was completed in November 2020.

The LeSoleil broad-spectrum anti-coronavirus protective and therapeutic spray is portable and easy to use. It effectively prevents healthy people from infection and blocks the spread of SARS-CoV-2 from asymptomatic and mild COVID-19 patients. LeSoleil broad-spectrum anti-coronavirus protective and therapeutic spray can cope with the prevention and treatment of SARS-CoV-2 and variant strains (e.g., Delta and Omicron.). In addition, the preclinical study conducted by the Suntrap team revealed that LeSoleil can also be used for upper respiratory tract infections caused by influenza viruses and mutant strains (e.g., H1N1, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 and H10N8). The new corresponding symptoms still need to be verified by clinical research.

The COVID-19 pandemic has continued for nearly two years. Mutant strains are constantly emerging, and the global incidence rate continues to rise. To date, the Suntrap research team has achieved a certain degree of breakthrough in the design of multi-target anti-coronavirus drugs. It is necessary to accelerate the clinical verification and strengthen cooperation. To further in-depth clinical research of LeSoleil anti-SARS-CoV-2 drugs, and deter COVID-19 as an obstacle for social stability, economic development and human health, Suntrap recruits qualified clinical research institutions around the world to carry out clinical revalidation studies on the efficacy of the LeSoleil broad-spectrum anti-coronavirus drug series against mutant strains of SARS-CoV-2.

Consult or search for “IDDNU” and “Suntrap” for related reports.


Zoe Zhou, Suntrap Life Technologies Ltd


T: +86-20-23889990

Topic: Press release summary

Japan – Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference

Eisai Co., Ltd. and Biogen Inc. announced today results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD). This presentation was made by Eisai at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference, November 9-12, 2021 in Boston, Massachusetts and virtually.

In September 2021, Eisai initiated a rolling submission of a Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early AD, to the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway.

Study 201, a multicenter, double-blind, placebo-controlled, Phase 2b trial conducted in 856 patients with early AD, evaluated key efficacy assessments, including clinical change on the Alzheimer’s Disease Composite Score (ADCOMS) at the primary endpoint of 12 months and at select key secondary endpoints, Clinical Dementia Rating-Sum-of-Boxes (CDR-SB) and Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) at 18 months. Six sensitivity analyses across four statistical models (mixed model for repeated measures, disease progression model, natural cubic spline model, and quadratic mixed model) showed consistent positive lecanemab treatment effects for ADCOMS, CDR-SB and ADAS-Cog14 at 18 months.

The primary endpoint was Bayesian analysis of 12-month clinical change on ADCOMS with the goal to identify the most efficacious dose (ED90 dose). Primary analysis was super-superiority over placebo by ≥25%: goal was 80% probability of >/=25% reduction in decline versus placebo. Study achieved the goal of identifying smallest dose that achieved ≥90% of maximum treatment effect (10 mg/kg biweekly), i.e., the ED90 dose. At 12 months, ED90 dose had 64% probability of being super-superior to placebo by 25% reduction. At 12 months, ED90 dose had 98% probability superior to placebo. Consistent treatment effect was observed at 18 months for ADCOMS (29% to 37%), CDR-SB (26.5% to 35%), and ADAS-Cog (47% to 56%), with separation from placebo observed by six months for the top dose (10mg/kg biweekly) across all analyses.

“In Study 201, lecanemab showed robust clearance of brain amyloid and slowing of clinical decline across several clinical and biomarker endpoints. This sensitivity analysis shows lecanemab clinical efficacy results across statistical models are consistent, reliable and further enhances our confidence in the clinical potential of this investigational therapy,” said Michael Irizarry, M.D., Vice President, Deputy Chief Clinical Officer, Neurology Business Group, Eisai Inc. “Through our comprehensive research program, we will continue to advance the understanding of how this anti-amyloid beta protofibril antibody may play a role in the treatment of early and preclinical AD. In March 2021, Eisai completed enrollment of 1,795 patients with early Alzheimer’s disease in our confirmatory Phase 3 Clarity AD clinical study. The Phase 3 clinical study, AHEAD 3-45, is currently exploring lecanemab’s safety and efficacy in individuals with preclinical AD.”

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

For more information, visit

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.